Financial Ratios

PHARMAIDS PHARMACEUTICALS LTD.

NSE : NABSE : 524572ISIN CODE : INE117D01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE64.78-1.32 (-2 %)
PREV CLOSE ( ) 66.10
OPEN PRICE ( ) 64.78
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 64.78 (12978)
VOLUME 15162
TODAY'S LOW / HIGH ( )64.78 64.78
52 WK LOW / HIGH ( ) 22.7879.23
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-3.520.140.090.03-0.17
   CEPS(Rs)-3.520.150.130.07-0.13
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)10.248.448.308.218.18
   Tax Rate(%)23.74-3.48-5.51108.94-24.00
Margin Ratios
   Core EBITDA Margin(%)3.481.25-18.13
   EBIT Margin(%)3.631.03-25.37
   Pre Tax Margin(%)3.561.03-25.49
   PAT Margin (%)3.681.09-31.60
   Cash Profit Margin (%)3.921.62-23.43
Performance Ratios
   ROA(%)-46.351.491.110.40-3.56
   ROE(%)-49.341.691.100.40-3.76
   ROCE(%)-63.941.661.04-4.45-3.02
   Asset Turnover(x)0.000.401.010.000.11
   Sales/Fixed Asset(x)0.007.7516.840.002.40
   Working Capital/Sales(x)0.0017.3631.820.000.13
Efficiency Ratios
   Fixed Capital/Sales(x)0.130.060.42
   Receivable days74.8611.83457.05
   Inventory Days58.2215.760.00
   Payable days861.23143.4611.46176.46
Valuation Parameters
   PER(x)0.0088.51122.99137.610.00
   PCE(x)-6.2083.2383.1163.88-36.79
   Price/Book(x)2.131.481.350.550.58
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)3.161.328.43
   EV/Core EBITDA(x)-3.4481.7384.65-13.71-48.99
   EV/EBIT(x)-3.4386.98127.55-12.29-33.21
   EV/CE(x)1.561.161.290.570.55
   M Cap / Sales3.261.348.62
Growth Ratio
   Net Sales Growth(%)-100.00-53.93-100.0024.93
   Core EBITDA Growth(%)-6595.4214.21139.72-247.7373.64
   EBIT Growth(%)-7025.0461.70123.62-162.9961.23
   PAT Growth(%)-5305.6755.55178.26118.9154.03
   EPS Growth(%)-2592.8655.49177.98118.9484.95
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)8.221.091.4615.4721.39
   Quick Ratio(x)8.220.730.8315.4721.39
   Interest Cover(x)-2139.3452.270.00-445.60-215.25
   Total Debt/Mcap(x)0.000.000.000.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.